Skip to content
Resources

Explainers, sourced.

Short explainers on how ZenReps works — assembled from the same claim-audited copy as the rest of this site. Nothing here sits behind a form.

Buyer's guide

Evaluating AI reps for regulated life-sciences promotion.

Ten questions to put to any vendor of AI reps for regulated promotion — what a good answer looks like at the outcome level, the red flags that generalize, and a pilot protocol that settles the question. Vendor-neutral by construction, ours included.

Read the guide
01Resources

How the gate decides

On the gated text channels — web chat and Telegram — a ZenRep's reply is constructed and checked before it reaches the HCP: grounded in your MLR-approved corpus, verified claim by claim, fair-balanced, and written to an inspectable record.

The gate rests on four guarantees — it can only speak approved material; every claim is checked before it's delivered; it refuses rather than guesses; every turn is audit-traceable. The full control list, in MLR language, is on the compliance page.

How the gate decides, in MLR language

02Resources

The ROI arithmetic, sourced

A human field team's cost-and-coverage arithmetic, figure by figure with primary sources, against what a ZenRep deployment changes.

The full arithmetic — cost per rep, cost per call, ramp, turnover — every figure footnoted to its source and rounded down — lives in the economics write-up.

The arithmetic of a field force, sourced

03Resources

Jurisdictions & posture

How the gate adapts to market and product class — Canada (PAAB / Health Canada) and the United States (FDA OPDP) today, for both drug and device — plus the EU/UK path and where the data lives.

Do you support the EU and UK?

Canada (PAAB) and the US (OPDP) are live today. The regulatory research is complete and provisional rulesets are authored; counsel review and productization remain before any EU or UK tenant goes live. EU is a near-term priority.

Residency that fits the law.

Canadian tenants run in ca-central-1 (Montreal) today; a US region stands up in-region when a US tenant onboards. Data residency by layer is detailed on the trust page.

Posture, on the record.

Every reply is grounded against your MLR-approved corpus and written to an append-only, per-turn audit record with database-enforced edit and deletion restrictions. Data residency by layer, subprocessors, and certification status are detailed on the trust page — rounded down.

04Resources
Explainer

Adverse events don't announce themselves

Doctors report adverse events in hedged, abbreviated, human language — and keyword screening misses the normal ones. How ZenReps reads for meaning, protects patient identity, and gets the report to your pharmacovigilance team.

When a physician mentions a patient who got hurt, they almost never say "adverse event." They don't speak in the language of your safety database. They speak like a busy clinician between appointments:

"Honestly probably has nothing to do with your drug — she's on a million things — but my patient's been getting these dizzy spells since we started her on it. Just flagging in case you've heard it before."
"Yeah, we ended up pulling the 78-year-old off it at week two — couldn't justify keeping her on once we saw how she was doing."
"pt c/o n/v + dizziness after 2nd dose, holding it for now till i see her thurs."

Every one of those is a reportable adverse event. The first hedges on causality and wraps the whole report in an apology. The second never names a single symptom — pulling the patient off the drug is the entire report. The third is shorthand a clinician types in three seconds.

A doctor will not rephrase these for you. They expect you to understand. And under pharmacovigilance rules, the obligation to recognize and report doesn't depend on how clearly the doctor said it.

Why keyword screening misses the normal ones

The traditional way to catch adverse events in conversation is a keyword list: flag the message if a trigger word — "rash," "nausea," "side effect" — appears. Keyword screening catches the obvious reports. But look again at the three messages above:

  • The dizzy-spells message does contain a symptom word — buried under "probably has nothing to do with your drug." A naive system reads that as the doctor ruling a problem out. The doctor is doing the opposite: flagging one.
  • The week-two message contains no symptom word at all. There is nothing for a keyword list to match.
  • "n/v" is clinician shorthand for nausea and vomiting. A list looking for the word "vomiting" sees nothing.

The reports that slip through keyword screening aren't the rare ones — they're the normal ones, phrased the way clinicians actually talk. A list of words can only catch the wordings someone thought to add to the list.

What ZenReps does

ZenReps reads every message from a healthcare professional for what it means, not just which words appear. It asks the question a keyword list can't: is this person describing something that happened to a patient on the drug? That's the question that catches the dizzy spells, the week-two discontinuation, and the shorthand.

Detection carries a deliberate bias: when it isn't sure, it errs toward flagging. A missed regulated report is a far worse outcome than a second look at a false alarm — so the system leans toward catching, and your pharmacovigilance team makes the final call.

Three guarantees that come with it

It never slows the conversation. The safety review happens in the background. The clinician experiences a normal, responsive conversation — the check adds no delay they can see.

It protects patient identity by design. Before anything is recorded, the shapes of patient-identifying information — email addresses, phone numbers, record numbers, dates, long strings of digits — are stripped out. What remains is the clinical substance of the report: the symptom, the timing, the fact that a patient came off the drug.

A human always has the final word. When a report is recognized, a structured adverse-event intake record is created — in the doctor's own words, identifiers removed — and your pharmacovigilance team is alerted to review and grade it. That record starts your reporting workflow so nothing reportable falls on the floor; it is not itself the regulatory filing. ZenReps doesn't decide severity, doesn't fill in regulatory fields, and doesn't make clinical judgments. Its job is to make sure the report reaches the people whose job that is.

In one paragraph

Doctors report adverse events in plain, hedged, abbreviated human language — "it didn't agree with her," "we pulled her off it," "probably nothing to do with your drug, but." Keyword screening catches the obvious ones and misses the normal ones. ZenReps reads each message for what it actually means, strips patient identifiers, files the structured intake record, and alerts your pharmacovigilance team — without slowing the conversation or making a single clinical judgment. A human on your side always grades the result.

ZenReps is a promotional-compliance tool for HCP-facing conversations. It captures and routes adverse-event reports for your pharmacovigilance team to review; it does not provide clinical decision support, diagnose, or grade severity. Specific performance figures and configuration details are available under NDA.

05Resources
FAQ

Adverse-event capture: questions pharmacovigilance and compliance teams ask

Straight answers to the questions safety and compliance reviewers put to AI-assisted adverse-event capture: reliability, patient privacy, latency, false alarms, and who keeps the final word.

How does it recognize a report a keyword filter would miss?

By reading for meaning instead of matching words. Real reports arrive as idioms, clinical shorthand, second-hand accounts, and causality hedges ("probably nothing to do with your drug, but…"). ZenReps asks whether the message describes something that happened to a patient on the drug — regardless of how it's phrased — so a report with no symptom keyword in it at all still gets caught.

Is AI detection reliable enough for safety reporting?

Detection errs toward flagging when unsure, and every captured report is reviewed and graded by your pharmacovigilance team — the system routes; it does not adjudicate. The most recent strengthening of detection shipped after offline validation, with live verification in progress; performance figures from our testing are available under NDA. The full mechanism is in the explainer above.

Will it slow our rep conversations down?

No. The review runs in the background and adds no delay the HCP can see — and a slow or failing check can never stall the conversation. How that works is in the explainer above.

What happens to patient information?

The shapes of patient-identifying information — email addresses, phone numbers, record numbers, dates, long strings of digits — are stripped before anything is recorded; what remains is the clinical substance your safety team needs. The full privacy design is in the explainer above.

Does it file the regulatory report for us?

No — deliberately. It creates the intake record that starts your reporting workflow and alerts your pharmacovigilance team; a human reviewer grades severity, completes the regulatory fields, and files. The tool makes sure nothing reportable falls on the floor — discharging the reporting obligation remains a judgment your team makes, exercised by people qualified to make it.

What if it flags something that turns out not to be an adverse event?

Then a reviewer reads it, marks it, and moves on — the cost is a short human look. The system is tuned on the view that a false alarm is recoverable and a missed regulated report is not. It is also built to catch without flooding: the goal is a signal your pharmacovigilance team trusts, not an inbox they learn to ignore. Your team keeps the final word on every flag.

Can our team evaluate it before it goes live?

Yes — and you should. Bring the hard cases: the hedged phrasings, the shorthand, the second-hand reports your team has seen missed before. Put them to the system during evaluation and read the intake records it produces. The evaluation should end with your pharmacovigilance and compliance reviewers judging real outputs, not a slide about them.

ZenReps is a promotional-compliance tool for HCP-facing conversations. It captures and routes adverse-event reports for your pharmacovigilance team to review; it does not provide clinical decision support, diagnose, or grade severity. Specific performance figures and configuration details are available under NDA.

This library grows. Everything published here is sourced, stated at the outcome level, and rounded down.